![Denis Ho](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Denis Ho
Directeur/Bestuurslid bij Rna Diagnostics, Inc.
Profiel
Denis Ho is currently the Director at Rna Diagnostics, Inc. and the Venture Partner at Relentless Pursuit Partners, Inc. Previously, he held positions as the Managing Director at BDC Venture Capital, Director at Trillium Therapeutics, Inc., Director at Interface Biologics, Inc., and Venture Partner at Lumira Capital Investment Management, Inc. Mr. Ho completed his graduate degree at Queen's University, his undergraduate degree at the University of Toronto, and his MBA at the University of Western Ontario.
Actieve functies van Denis Ho
Bedrijven | Functie | Begin |
---|---|---|
Rna Diagnostics, Inc.
![]() Rna Diagnostics, Inc. Medical SpecialtiesHealth Technology Rna Diagnostics, Inc. operates as a cancer diagnostics company which builds a platform of prognostic biomarker tools to help improve the lives of patients undergoing chemotherapy. The firm develops prognostic biomarker tools to improve the lives of women undergoing chemotherapy for breast cancer. It provides The RNA Disruption Assay (RDA), which provides physicians with an evaluation of how individual patients are responding to chemotherapy. The company was founded by Kenneth P. H. Pritzker in 2010 and is headquartered in Toronto, Canada. | Directeur/Bestuurslid | - |
Relentless Pursuit Partners, Inc.
![]() Relentless Pursuit Partners, Inc. Investment ManagersFinance Founded by Simon Whitfield and Brenda Irwin in 2014, Relentless Pursuit Partnrs Inc is a venture capital firm headquartered in Canada. | Consultant / Adviseur | - |
Eerdere bekende functies van Denis Ho
Bedrijven | Functie | Einde |
---|---|---|
Trillium Therapeutics, Inc. /Old/
![]() Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | Directeur/Bestuurslid | 06-06-2014 |
Lumira Capital Investment Management, Inc.
![]() Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | Private Equity Investor | - |
Interface Biologics, Inc.
![]() Interface Biologics, Inc. Information Technology ServicesTechnology Services Interface Biologics, Inc. operates as a commercial stage privately held company that develops transformative biomedical polymer technologies to improve the safety and effectiveness of medical devices. It provides technologies to medical device manufacturers and drug companies. The company was founded by Paul J. Santerre in December 2001 and is headquartered in Toronto, Canada. | Directeur/Bestuurslid | - |
BDC Venture Capital
![]() BDC Venture Capital Investment ManagersFinance BDC Venture Capital (BDC Venture Capital) is a venture capital firm founded in 1975. The firm is headquartered in Québec, Canada. | Head-Equity Investments | 11-06-2009 |
Opleiding van Denis Ho
Queen's University | Graduate Degree |
University of Toronto | Undergraduate Degree |
University of Western Ontario | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 6 |
---|---|
Lumira Capital Investment Management, Inc.
![]() Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | Finance |
BDC Venture Capital
![]() BDC Venture Capital Investment ManagersFinance BDC Venture Capital (BDC Venture Capital) is a venture capital firm founded in 1975. The firm is headquartered in Québec, Canada. | Finance |
Trillium Therapeutics, Inc. /Old/
![]() Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | Commercial Services |
Interface Biologics, Inc.
![]() Interface Biologics, Inc. Information Technology ServicesTechnology Services Interface Biologics, Inc. operates as a commercial stage privately held company that develops transformative biomedical polymer technologies to improve the safety and effectiveness of medical devices. It provides technologies to medical device manufacturers and drug companies. The company was founded by Paul J. Santerre in December 2001 and is headquartered in Toronto, Canada. | Technology Services |
Relentless Pursuit Partners, Inc.
![]() Relentless Pursuit Partners, Inc. Investment ManagersFinance Founded by Simon Whitfield and Brenda Irwin in 2014, Relentless Pursuit Partnrs Inc is a venture capital firm headquartered in Canada. | Finance |
Rna Diagnostics, Inc.
![]() Rna Diagnostics, Inc. Medical SpecialtiesHealth Technology Rna Diagnostics, Inc. operates as a cancer diagnostics company which builds a platform of prognostic biomarker tools to help improve the lives of patients undergoing chemotherapy. The firm develops prognostic biomarker tools to improve the lives of women undergoing chemotherapy for breast cancer. It provides The RNA Disruption Assay (RDA), which provides physicians with an evaluation of how individual patients are responding to chemotherapy. The company was founded by Kenneth P. H. Pritzker in 2010 and is headquartered in Toronto, Canada. | Health Technology |